A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects With Persistent Asthma

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects With Persistent Asthma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2015

At a glance

  • Drugs MK 1029 (Primary) ; Montelukast
  • Indications Asthma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 21 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Apr 2013 Planned End Date changed from 1 Nov 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 22 Dec 2012 Additional lead trial centre identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top